Helen Torley - PRESIDENT AND CEO, Director at HALOZYME THERAPEUTICS, INC.

Issuer-level insider activity

Role
PRESIDENT AND CEO, Director
Issuer ticker
HALO on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

Past-year transaction volume for Helen Torley in HALOZYME THERAPEUTICS, INC.

Buys

Open market
Shares
Avg price
Total value

Sells

Open market
Shares
-508,492
Avg price
$74.45
Total value
-$37,855,970

Net

Past year
Shares
-508,492
Share %
-100%
Total value
-$37,855,970

Reported holdings for Helen Torley in HALOZYME THERAPEUTICS, INC.

Form 4 holding PRESIDENT AND CEO, Director

HALOZYME THERAPEUTICS, INC.

Security class
Restricted Stock Units
Shares / value
44,872
Estimated value
$3,923,383
Report date
23 Feb 2026
Price
$58.29
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding PRESIDENT AND CEO, Director

HALOZYME THERAPEUTICS, INC.

Security class
Option to Purchase Common Stock
Shares / value
141,552
Estimated value
$2,437,210
Report date
19 Aug 2026
Price
$12.07
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for Helen Torley in HALOZYME THERAPEUTICS, INC.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .